健世科技

Jenscare Scientific Co., Ltd.
寧波健世科技股份有限公司

(A joint stock Company incorporated in the People's Republic of China with limited liability)
(Stock Code: 9877)

VOLUNTARY ANNOUNCEMENT
The Registration Approval of JensClip by NMPA and Its Active Commercialization

This announcement is made by Jenscare Scientific Co., Ltd. (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide the shareholders and potential investors of the Company with updated information in relation to the latest business and new product development of the Group.

The Board (the "**Board**") of Directors (the "**Director(s)**") of the Company is pleased to announce that one of the Company's core proprietary products, JensClip Transcatheter Valve Repaire System ("**JensClip**"), has recently received registration approval from the National Medical Products Administration ("**NMPA**"). The Company is actively pursuing the commercialization and clinical applications of JensClip in the Chinese mainland and other markets and continues to advance the device's global expansion.

JensClip, the Company's proprietary Transcatheter Mitral Valve Repair Clip System, is designed to treat patients with severe mitral regurgitation. The JensClip system introduces an innovative self-locking design which will effectively reduce mitral regurgitation. Featuring a linkage mechanism that allows for flexible shape adjustment, the valve clip is expected to effectively improve procedural safety. At the same time, the device enables both simultaneous bilateral and unilateral leaflet capture to enhance procedural adaptability. An integrated detachment mechanism minimizes potential risks of accidental deployment errors and effectively shortens procedural time.

Leveraging its existing resources and platforms, the Company will continue to advance the commercialization of JensClip in the domestic market, while actively pursuing CE MDR registration and other overseas registration approvals and increasing commercialization efforts. The globalization process of JensClip is also being actively advanced and compassionate use programs have been extensively conducted overseas to treat patients, with all procedures progressing smoothly and the product performance being excellent. With the obtaining of registration approval for products covering aortic, mitral and tricuspid diseases in different markets, the Company's domestic and overseas commercialization will create synergy for its multiple products. This momentum will unlock long-term growth potential and build a robust global growth curve.

Upon obtaining NMPA registration approval for the JensClip, the Company's product portfolio covers three major valve areas in interventional treatments for structural heart diseases. The Company will implement a variety of measures to capture market opportunities in interventional treatments for structural heart disease and continuously expand its sales network and reach among target customers.

Cautionary Statement as required by Rule 18A.08(3) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited: There is no assurance that the Company will ultimately develop, market and/or commercialize JensClip successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board
Jenscare Scientific Co., Ltd.
Mr. PAN Fei
Executive Director and Chief Executive Officer

Hong Kong, 22 September 2026

As at the date of this announcement, the executive Director is Mr. PAN Fei; the non-executive Directors are Mr. LV Shiwen, Mr. TAN Ching, Mr. ZHENG Jiaqi, Ms. XIE Youpei and Mr. CHEN Xinxing; and the independent non-executive Directors are Dr. LIN Shoukang, Ms. DU Jiliu and Dr. MEI Lehe.